Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The benefit of induction chemotherapy in patients age > or = 75 years.
Vey N, Coso D, Bardou VJ, Stoppa AM, Braud AC, Bouabdallah R, Sainty D, Mozziconacci MJ, Lafage M, Damaj G, Blaise D, Gastaut JA, Maraninchi D. Vey N, et al. Cancer. 2004 Jul 15;101(2):325-31. doi: 10.1002/cncr.20353. Cancer. 2004. PMID: 15241830 Free article.
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N. Prebet T, et al. Among authors: vey n. Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721 Free article.
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Crocchiolo R, Esterni B, Castagna L, Fürst S, El-Cheikh J, Devillier R, Granata A, Oudin C, Calmels B, Chabannon C, Bouabdallah R, Vey N, Blaise D. Crocchiolo R, et al. Among authors: vey n. Cancer. 2013 Mar 1;119(5):986-92. doi: 10.1002/cncr.27858. Epub 2012 Oct 23. Cancer. 2013. PMID: 23096591 Free article.
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Borthakur G, et al. Among authors: vey n. Cancer. 2016 Jun 15;122(12):1871-9. doi: 10.1002/cncr.29986. Epub 2016 Mar 18. Cancer. 2016. PMID: 26990290 Free PMC article. Clinical Trial.
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.
Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C. Bertoli S, et al. Among authors: vey n. Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262. Oncotarget. 2016. PMID: 27852053 Free PMC article.
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.
Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, Salles G, Gonçalves A. Vey N, et al. Oncotarget. 2018 Apr 3;9(25):17675-17688. doi: 10.18632/oncotarget.24832. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707140 Free PMC article.
398 results